Drug Profile
Research programme: Alzheimer's disease therapeutics - Daewoong Pharmaceutical
Alternative Names: DWJ 501Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Daewoong Pharmaceutical
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Alzheimer's-disease in South Korea (PO)
- 16 Mar 2011 This programme is still in active development
- 31 May 2009 Preclinical trials in Alzheimer's disease in South Korea (PO)